Status:
RECRUITING
An Exploratory Clinical Study on the Safety and Efficacy of Autologous NK Cells in the Treatment of Pulmonary Nodules
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Collaborating Sponsors:
Rui Therapeutics Co., Ltd
Conditions:
Pulmonary Nodules, Solitary
Pulmonary Nodules, Multiple
Eligibility:
All Genders
18-70 years
Phase:
EARLY_PHASE1
Brief Summary
A single-center, open-label dose-escalation design to evaluate the safety and efficacy of KN5001 in patients with pulmonary nodules.
Eligibility Criteria
Inclusion
- Subjects voluntarily sign the informed consent form, understand this clinical study, and are willing to follow and able to complete all trial procedures;
- 18-70 years old, male or female;
- Subjects with lung nodules confirmed by imaging examination must meet the following conditions:
- Multiple high-risk nodules have been surgically removed and confirmed to be malignant lesions, and the remaining high-risk nodules (refer to the standards in Appendix 12) cannot be surgically removed again, and are not suitable for other effective treatments or have failed other treatments;
- If the subject is unable to complete the puncture or the puncture fails, the subject must be diagnosed as a malignant nodule through PET-CT imaging examination.
Exclusion
- Subjects who are known to have allergic reactions, hypersensitivity reactions, intolerances or contraindications to any component of KN5001, or subjects with a history of severe allergic reactions;
- Subjects with the following genetic syndromes: Fanconi syndrome, Kostmann syndrome, Shwachman syndrome or any known bone marrow failure syndrome;
- Subjects with active or uncontrolled infections requiring parenteral antibiotics; Evidence of a serious active viral or bacterial infection or an uncontrolled systemic fungal infection;
- Subjects with heart failure of grade III or IV according to the New York Heart Association (NYHA) cardiac function classification standard (see Appendix 1);
- Subjects with a history of epilepsy or other central nervous system diseases;
- Subjects with a history of malignant tumors, excluding patients with cured skin or cervical carcinoma in situ and patients with inactive tumors;
- Subjects with a significant bleeding tendency, such as gastrointestinal bleeding, coagulopathy, hypersplenism, etc.;
- Subjects with unstable angina, symptomatic congestive heart failure, or myocardial infarction in the past 6 months;
- Females who are pregnant, lactating, or planning a pregnancy within six months;
- Subjects who have received other clinical trial treatment within 3 months;
- Any situation judged by the investigators that may increase the risk of the subjects or interfere with the clinical trial outcome.
Key Trial Info
Start Date :
September 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 20 2027
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT07185035
Start Date
September 20 2025
End Date
September 20 2027
Last Update
December 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital with Nanjing Medical University
Nanjing, China